Pralidoxime
Solicitation number W6369-26-A033
Publication date
Closing date and time 2026/01/22 14:00 EST
Last amendment date
Description
The Department of National Defence (DND) through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, has a requirement for Pralidoxime for the treatment of Canadian Armed Forces (CAF) members suspected of exposure to chemical warfare agents.
The initial requirement is for the delivery of 1,025 doses to be delivered before 31 March 2026. Optional requirements of 4,100 doses to be requested and delivered between 01 April 2026 and 31 March 2030.
There are no security requirements associated with this requirement.
The Crown retains the rights to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
Policy on Reciprocal Procurement: This solicitation of offers is open only to Canadian suppliers (if subject to any international trade agreement(s)): and to Suppliers of an applicable trading partner.
Contract duration
The estimated contract period will be 49 month(s), with a proposed start date of 2026/02/18.
Trade agreements
-
Please refer to tender description or tender documents
Reason for limited tendering
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below:
-
None
Contact information
Contracting organization
- Organization
-
Department of National Defence (DND)
- Address
-
101 Colonel By Drive
Ottawa, Ontario, K1A 0K2Canada
- Contracting authority
- Stephen Brown
- Phone
- (343) 630-0031
- Email
- Stephen.Brown2@forces.gc.ca
- Address
-
101 Colonel By Drive
Ottawa, Ontario, K1A 0K2Canada
Bidding details
| Document title | Amendment no. | Language | Unique downloads | Date added |
|---|---|---|---|---|
| W6369-24-A033_-_RFP_-_AMD001_-_FR.pdf | 001 | FR | 6 | 2025/12/23 |
| W6369-24-A033_-_RFP_-_AMD001_-_ENG.pdf | 001 | EN | 9 | 2025/12/23 |
| W6369-26-A033_-_RFP_Pralidoxime_French.pdf | 001 | FR | 7 | 2025/12/01 |
| W6369-26-A033_-_RFP_Pralidoxime.pdf | 001 | EN | 25 | 2025/12/01 |